Loading...

Shigeki Nanjo, MD, PhD

TitlePostdoctoral Scholar
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address600 16th St
San Francisco CA 94158
Phone415-476-9907
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y. Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. Oncotarget. 2017 Dec 26; 8(69):113807-113816. PMID: 29371947.
      View in: PubMed
    2. Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Irie K, Okada H, Fukushima S, Katakami N. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer. 2018 Jan; 118(1):32-37. PMID: 29190637.
      View in: PubMed
    3. Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. Lung Cancer. 2017 Sep; 111:182-189. PMID: 28838391.
      View in: PubMed
    4. Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Imai Y. Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo. 2017 May-Jun; 31(3):475-479. PMID: 28438882.
      View in: PubMed
    5. Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol Cancer Ther. 2017 Mar; 16(3):506-515. PMID: 28138027.
      View in: PubMed
    6. Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Nanjo S, Yamada T, Ohtsubo K, Yano S, Mizokami A. Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). J Med Invest. 2017; 64(3.4):202-204. PMID: 28954982.
      View in: PubMed
    7. Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Cancer Sci. 2017 Jan; 108(1):53-60. PMID: 27783866.
      View in: PubMed
    8. Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S, Okada Y, Nakada M, Murakami T, Yano S. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget. 2016 Jan 26; 7(4):3847-56. PMID: 26716903; PMCID: PMC4826174.
      View in: PubMed, PubMed Central
    9. Tanimoto A, Takeuchi S, Yaegashi H, Kotani H, Kitai H, Nanjo S, Ebi H, Yamashita K, Mouri H, Ohtsubo K, Ikeda H, Yano S. Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Mol Clin Oncol. 2016 Apr; 4(4):537-540. PMID: 27073657.
      View in: PubMed
    10. Takeuchi S, Fukuda K, Arai S, Nanjo S, Kita K, Yamada T, Hara E, Nishihara H, Uehara H, Yano S. Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. Int J Cancer. 2016 Mar 01; 138(5):1281-9. PMID: 26379118.
      View in: PubMed
    11. Hata A, Katakami N, Fujita S, Nanjo S, Takeshita J, Tanaka K, Kaneda T, Nishiyama A, Nishimura T, Nakagawa A, Otsuka K, Morita S, Urata Y, Negoro S. A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002). Cancer Chemother Pharmacol. 2015 Jun; 75(6):1267-72. PMID: 25925001.
      View in: PubMed
    12. Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Cancer Sci. 2015 Mar; 106(3):244-52. PMID: 25581823; PMCID: PMC4376432.
      View in: PubMed, PubMed Central
    13. Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 2014 Jul 15; 5(13):4920-8. PMID: 24952482; PMCID: PMC4148110.
      View in: PubMed, PubMed Central
    14. Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun; 9(6):775-83. PMID: 24828661; PMCID: PMC4132034.
      View in: PubMed, PubMed Central
    15. Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One. 2013; 8(12):e84700. PMID: 24386407; PMCID: PMC3873434.
      View in: PubMed, PubMed Central
    16. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013 Dec 15; 119(24):4325-32. PMID: 24105277.
      View in: PubMed
    17. Ohtsubo K, Ishikawa D, Nanjo S, Takeuchi S, Yamada T, Mouri H, Yamashita K, Yasumoto K, Gabata T, Matsui O, Ikeda H, Takamatsu Y, Iwakami S, Yano S. Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOP. 2013 Sep 10; 14(5):515-20. PMID: 24018598.
      View in: PubMed
    18. Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 2013; 8(5):e62104. PMID: 23690929.
      View in: PubMed
    19. Hata A, Fujita S, Kaji R, Nanjo S, Katakami N. Dose reduction or intermittent administration of erlotinib: which is better for patients suffering from intolerable toxicities? Intern Med. 2013; 52(5):599-603. PMID: 23448772.
      View in: PubMed
    20. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer. 2013 Jul 15; 133(2):505-13. PMID: 23319394.
      View in: PubMed
    21. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013 Apr 15; 73(8):2428-34. PMID: 23382048.
      View in: PubMed
    22. Konishi A, Kitada N, Nanjo S, Tanaka S, Tomii K, Katakami N, Hashida T. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer]. Gan To Kagaku Ryoho. 2012 Oct; 39(10):1507-10. PMID: 23064061.
      View in: PubMed
    23. Yamashita K, Ishikawa D, Nanjo S, Takeuchi S, Yamada T, Mouri H, Ohtsubo K, Yasumoto K, Kumagai M, Ueda Y, Yano S. [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]. Gan To Kagaku Ryoho. 2012 Sep; 39(9):1427-30. PMID: 22996784.
      View in: PubMed
    24. Yamada T, Ohtsubo K, Ishikawa D, Nanjo S, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Yano S. [Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective]. Gan To Kagaku Ryoho. 2012 Aug; 39(8):1291-4. PMID: 22902462.
      View in: PubMed
    25. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct; 11(10):2149-57. PMID: 22844075.
      View in: PubMed
    26. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 01; 18(13):3592-602. PMID: 22553343.
      View in: PubMed
    27. Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, Otsuka K, Kaji R, Hayashi M, Katakami N, Imai Y. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012; 83(1):20-7. PMID: 21912082.
      View in: PubMed
    28. Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011 Nov; 74(2):268-73. PMID: 21529987.
      View in: PubMed
    29. Hata A, Katakami N, Masuda Y, Nanjo S, Otsuka K, Kaji R, Fujita S, Iwamori S, Mifune Y, Orita H, Fukae M, Yamatani T. [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. Gan To Kagaku Ryoho. 2011 Mar; 38(3):415-8. PMID: 21403444.
      View in: PubMed
    30. Nagata K, Tomii K, Nanjo S, Kubota M, Tachikawa R, Nishio M. [Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody]. Nihon Kokyuki Gakkai Zasshi. 2011 Jan; 49(1):30-6. PMID: 21384679.
      View in: PubMed
    31. Hata A, Katakami N, Fujita S, Kaji R, Nanjo S, Otsuka K, Kida Y, Higashi Y, Tachikawa R, Hayashi M, Nishimura T, Tomii K. Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer. Lung Cancer. 2011 May; 72(2):224-8. PMID: 20828862.
      View in: PubMed
    32. Hata A, Nanjo S, Otsuka K, Kida Y, Higashi Y, Kaji R, Fujita S, Katakami N. [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies]. Gan To Kagaku Ryoho. 2009 May; 36(5):807-10. PMID: 19461182.
      View in: PubMed
    Shigeki's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (192) concept(s)
    _
    ↑